How Europe May Respond to U.S. Drug Pricing Policies

U.S. pharmaceutical pricing policies are beginning to influence decisions well beyond the United States. European governments are concerned about what these changes could mean for medicine launches, investment, manufacturing, and patient access.

On October 15, the European Parliament's Public Health Committee voted to ask the European Commission and Council of the EU how they intend to respond to U.S. pricing and trade policies, including most-favored-nation (MFN) drug pricing and potential pharmaceutical tariffs.

I recently spoke with Francesca Bruce at Pink Sheet about what a European response might look like.

Why This Matters to Pharmaceutical Companies

Under an MFN approach, certain U.S. drug prices would be linked to prices in other countries.

That creates a difficult decision for manufacturers. If a lower European price affects what a company can earn in the United States, the company may reconsider when and where to launch a new medicine.

European governments are concerned that some patients could wait longer for access to innovative treatments. Manufacturers must also consider how pricing decisions affect future investment and expected revenue.

These concerns are becoming more important as the United States examines European pharmaceutical pricing practices through trade investigations, including the current Section 301 investigation involving Germany.

What Europe Could Do

Europe cannot simply establish a single pharmaceutical pricing system overnight. Pricing and reimbursement remain largely national responsibilities.

As I discussed with Pink Sheet, a more likely response would involve EU member states cooperating more closely while retaining control over their own reimbursement decisions.

That could include joint purchasing arrangements, better coordination of clinical assessments, faster regulatory procedures, and policies intended to encourage pharmaceutical research and manufacturing.

One opportunity involves the EU's Joint Clinical Assessment (JCA) process.

JCAs allow member states to assess clinical evidence for certain new medicines together. However, countries may request overlapping information during the assessment process.

Better coordination could reduce some of that duplication, saving manufacturers time and resources. More consistent use of the resulting clinical reports could also help national authorities without requiring countries to adopt identical reimbursement decisions.

What Companies Should Be Watching

For pharmaceutical executives, these developments raise several business questions.

Will lower prices in individual European countries affect U.S. revenue expectations? Could international pricing policies influence launch sequencing? Will changes to European clinical assessments reduce regulatory work? Could trade investigations create additional uncertainty for companies operating in both markets?

These questions matter to established manufacturers and smaller biotechnology companies alike. Expected pricing and reimbursement can affect investment decisions, licensing negotiations, and the commercial value of products still in development.

The European Parliament's action does not change existing pricing laws. It does show that European policymakers are taking the potential consequences of U.S. pharmaceutical policy seriously.

For companies operating internationally, it is worth following how national governments and EU institutions respond. Decisions made on either side of the Atlantic could affect where new medicines are launched, how they are priced, and where future investments are made.

Ron Lanton is Senior Partner and Global Strategist at Lanton, Lanton & Sosa Law PLLC. The firm advises healthcare and life sciences organizations on regulatory, pharmaceutical policy, and business matters.

Related coverage: Francesca Bruce, Pink Sheet, October 20, 2026, “Influential EU Parliament Committee Pushes Commission And Council On US Drug Pricing Measures.”

This article is for general informational purposes and does not constitute legal advice.